In particular, substantial observational and real-world data document significant, albeit indirect, signals about the modulatory effects of SGLT-2 inhibitors on AF, one of the most common arrhythmias associated with a high burden of strokes and thromboembolism [18,22]. The gene discussed is SLC5A2; the disease is atrial fibrillation.